S 05985 combination versus AT1-Receptor Blocker/thiazide: a comparison of blood pressure lowering - efficacy and safety

Perindopril Amlodipine Regimen versus AT1-Receptor Blocker/thiazide: a comparison of Blood pressure Lowering: Efficacy and Safety. A randomised, double blind, 9 month study of the efficacy and safety of four uptitrated doses of oral fixed combinations of perindopril/amlodipine, including a comparison with uptitrated doses of oral fixed combination of irbesartan and hydrochlorthiazide in mild to moderate hypertension.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN61335805

Enrollment

3000

Registered

2008-02-29

Start date

2007-12-05

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential arterial hypertension Circulatory System Hypertension

Interventions

S 05985 combination versus AT1-Receptor Blocker/ thiazide for 9 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men or women 2. Over 18 years 3. Essential arterial hypertension

Exclusion criteria

Exclusion criteria: 1. Pregnancy, breast-feeding, childbearing potential without medically accepted method of contraception 2. Acute or chronic illness 3. Secondary hypertension 4. Malignant hypertension 5. Clinical symptomatic hypotension

Design outcomes

Primary

Measure	Time frame
1. Overall proportion of participants with controlled blood pressure (at 6 months) 2. Safety assessment	—

Secondary

Measure	Time frame
1. Efficacy versus comparator (at 6 months) 2. New onset of clinical events or condition of special interest	—

Countries

Ireland, Netherlands, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026